Dipharma and Alvogen launch Diterin in South Korea

Generic drugmakers Switzerland’s Dipharma and USA-based Alvogen have announced the launch of  Diterin (sapropterin dihydrochloride 100mg tablets), indicated for the treatment of hyperphenylalaninemia (HPA) due to phenylketonuria (PKU), in the Republic of South Korea.

Diterin is the only drug approved in South Korea by the Korean Ministry of Food and Drug Safety for the treatment of HPA due to PKU, a rare genetic disease leading to an abnormally high concentration of phenylalanine (Phe) in the blood, which can cause brain damage to people affected by it.

“We are happy to provide Diterin to the South Korean market, as this treatment can make a difference in the management of Phe levels for many patients suffering from lifelong PKU, contributing to prevent the appearance of potential transient to non-reversible mental impairment” said Peter Vazharov, Alvogen S&M vice president, Asia Pacific together with Marc-Olivier Geinoz, chief executive of Dipharma, who added: “As part of Dipharma’s mission, we will continue to expand our portfolio of high-quality products – including Diterin – to offer improved solutions to each and every patient suffering from inborn errors of metabolism all around the world”.